Toll样受体激动剂在变应性气道炎性疾病治疗中的研究进展

Research progress of Toll-like receptor agonists in treatment of allergic airway inflammatory disease

Toll样受体(TLRs)是模式识别受体中的一个大家族,是形成有效和完善的适应性免疫的关键因素,与Th2向Th1的表型转化和调节性T细胞的成熟密切相关。TLRs激动剂作为免疫佐剂或者独立的免疫制剂,在变应性哮喘、变应性鼻炎(AR)等变应性气道炎性疾病的治疗中展现出广泛的应用前景。本文总结了TLRs激动剂在变应性气道炎性疾病的临床前及临床免疫治疗中的最新研究成果。

Toll-like receptors(TLRs),a large family of pattern recognition receptors,are key factors in the formation of effective and well-developed adaptive immunity,which are closely related to the differentiation of Th2 to Th1 phenotypes and the maturation of regulatory T cells.TLRs agonists,as immune adjuvants or independent immune agents,have shown broad application prospects in the treatment of allergic airway inflammatory diseases such as allergic asthma and allergic rhinitis(AR).This paper summarize the latest findings of TLRs agonists in the preclinical and clinical immunotherapy of allergic airway inflammatory diseases.